Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: A cohort study

Blood

Volumn 131, Issue 7, 2018, Pages 797-807

  Cieslik, Joanna ^a   Mrozinska, Sandra ^b,c   Broniatowska, Elzbieta ^b   Undas, Anetta ^b,d  

^a Military Clinical Hospital Krakow   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^d Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; C REACTIVE PROTEIN; D DIMER; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DEGRADATION; EUGLOBULIN LYSIS TEST; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; FOLLOW UP; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PERMEABILITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME; TURBIDITY; ADOLESCENT; AGED; BLOOD; BLOOD CLOTTING; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; VEIN THROMBOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION; COHORT STUDIES; FEMALE; FIBRIN CLOT LYSIS TIME; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 85042167746     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-07-798306     Document Type: Article

References (41)

1. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1): 3-14.
2. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19): 1710-1716.
3. Weitz JI, Jaffer IH. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. Pol Arch Med Wewn. 2016;126(9):688-696.
4. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160(6): 769-774.
5. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205.
6. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-1636.
7. Zabczyk M, Plens K, Wojtowicz W, Undas A. Prothrombotic fibrin clot phenotype is associated with recurrent pulmonary embolism after discontinuation of anticoagulant therapy. Arterioscler Thromb Vasc Biol. 2017;37(2): 365-373.
8. Kyrle PA, Kammer M, Eischer L, et al. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. J Thromb Haemost. 2016;14(12):2402-2409.
9. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376(9757):2032-2039.
10. Sundquist K, Sundquist J, Svensson PJ, Zöller B, Memon AA. Role of family history of venous thromboembolism and thrombophilia as predictors of recurrence: a prospective followup study. J Thromb Haemost. 2015;13(12): 2180-2186.
11. Undas A, Ariëns RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011;31(12): e88-e99.
12. Bridge KI, Philippou H, Ariëns R. Clot properties and cardiovascular disease. Thromb Haemost. 2014;112(5):901-908.
13. Undas A. Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemost. 2014;112(1):32-42.
14. Undas A, Zawilska K, Ciesla-Dul M, et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood. 2009; 114(19):4272-4278.
15. Mazur P, Gawe da B, Natorska J, et al. Fibrin structure in organized thrombotic material removed during pulmonary artery endarter-ectormy: the effect of vessel calibre. J Thromb Thrombolysis. 2016;42(2):212-217.
16. Undas A, Ciesla-Dul ´ M, Dra zkiewicz T, Sadowski J. Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform. Thromb Res. 2012;130(3):e184-e187.
17. Siudut J, Grela M, Wypasek E, Plens K, Undas A. Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome. J Thromb Haemost. 2016;14(4):784-793.
18. Traby L, Kollars M, Eischer L, Eichinger S, Kyrle PA. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS One. 2012;7(12):e51447.
19. Karasu A, Baglin TP, Luddington R, Baglin CA, van Hylckama Vlieg A. Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis. Br J Haematol. 2016;172(6):947-953.
20. Meltzer ME, Bol L, Rosendaal FR, Lisman T, Cannegieter SC. Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS follow-up study. J Thromb Haemost. 2010;8(3):605-607.
21. Za bczyk M, Blombäck M, Majewski J, et al. Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger. Thromb Haemost. 2015;113(4):851-861.
22. Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006;4(5): 1029-1036.
23. Collet JP, Mishal Z, Lesty C, et al. Abnormal fibrin clot architecture in nephritic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Thromb Haemost. 1999;82(5):1482-1489.
24. Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96(5):553-561.
25. Meus R, Son M, Sobczyk D, Undas A. Prothrombotic state in patients with a left atrial appendage thrombus of unknown origin and cerebrovascular events. Stroke. 2016;47(7): 1872-1878.
26. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2016. https://www.R-project.org/.
27. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149-1160.
28. Becattini C, Agnelli G, Schenone A, et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959-1967.
29. Brighton TA, Eikelboom JW, Mann K, et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979-1987.
30. Undas A, Brummel-Ziedins K, Mann KG. Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. J Thromb Haemost. 2014;12(11):1776-1787.
31. Andreozzi GM, Bignamini AA, Davì G, et al; SURVET Study Investigators. Sulodexide for the prevention of recurrent venous thromboembolism: the Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 2015;132(20):1891-1897.
32. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006; 296(4):397-402.
33. Bruinstroop E, Klok FA, Van De Ree MA, Oosterwijk FL, Huisman MV. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost. 2009;7(4): 611-618.
34. Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003; 108(3):313-318.
35. Zolcinski M, Ciesla-Dul M, Undas A. Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism. Thromb Haemost. 2012;107(6):1180-1182.
36. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113(8):636-642.
37. Quist-Paulsen P, Naess IA, Cannegieter SC, et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica. 2010;95(1):119-125.
38. Undas A, Topór-Madry R, Tracz W, Pasowicz M. Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis. Thromb Haemost. 2009;102(6): 1289-1291.
39. Barua RS, Sy F, Srikanth S, et al. Acute cigarette smoke exposure reduces clot lysis–association between altered fibrin architecture and the response to t-PA. Thromb Res. 2010;126(5): 426-430.
40. Barua RS, Sy F, Srikanth S, et al. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler Thromb Vasc Biol. 2010;30(1): 75-79.
41. Zalewski J, Bogaert J, Sadowski M, et al. Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction. Thromb Haemost. 2015;113(6):1258-1269.